ArticleJournal of diabetes research2026
Sex Hormone-Based Models Outperform Conventional Scores for Metabolic Dysfunction-Associated Steatotic Liver Disease Screening: A Sex-Specific Analysis in Type 2 Diabetes.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among patients with Type 2 diabetes mellitus (T2DM). Although various noninvasive assessment tools for MASLD are currently available, few have been specifically validated in T2DM populations. Furthermore, the role of sex hormones in MASLD and their potential influence on cardiovascular and renal outcomes remain incompletely understood.
methodsIn this cross-sectional study of 731 Chinese patients with T2DM, we evaluated associations of testosterone and estradiol with MASLD, cardiovascular risk, and renal function. Sex hormone-based logistic regression models were constructed and compared with established noninvasive MASLD scores to assess their discriminative performance.
resultsIn male patients, higher testosterone, T/E2 ratio, FSH, and LH levels were inversely associated with MASLD, whereas higher DHEA levels were associated with an increased likelihood of MASLD. In female patients, higher DHEA levels were positively associated with MASLD, whereas prolactin showed a modest inverse association. After multivariable adjustment, testosterone remained independently and inversely associated with MASLD in males. Sex hormone-based models demonstrated better discriminative performance than conventional noninvasive scoring systems for MASLD. Additionally, testosterone was inversely associated with the ApoB/ApoA1 ratio in males, whereas estradiol was positively associated with eGFR in females.
conclusionIn patients with T2DM, testosterone and estradiol showed sex-specific associations with metabolic outcomes. Sex hormone-based models may provide a useful noninvasive approach for MASLD screening and risk assessment in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.